{"url_path":"/sec/otlc/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use Of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-023181-index.html","accession_number":"0001493152-26-023181","cik":"0000908259","ticker":"OTLC","issuer_name":"Oncotelic Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-023181-index.html","primary_entity_key":"0000908259","primary_entity_name":"Oncotelic Therapeutics, Inc."},"word_count":40,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use Of Proceeds**\n\n \n\nIn\nJanuary 2026, the Company issued 1,600,446 shares of Common Stock to Mast Hill as additional consideration in connection with the issuance\nof a $398,333 senior secured promissory note."}